High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial
DiscussionThis randomized clinical trial will demonstrate the clinical benefit of IMPT in esophageal cancer treatment in terms of survival and toxicity outcomes which will further establish high-level evidence for radiation modality in squamous cell carcinoma of the thoracic esophagus.Trial registrationTCTR20200310006. Registered 10 March 2020.
Source: Trials - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Esophagus Cancer | Heart | Hepatocellular Carcinoma | Intensity-Modulated Radiation Therapy | Liver | Liver Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Proton Therapy | Radiation Therapy | Research | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology | Tracheo-Esophageal Fistula | Urology & Nephrology